These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37782315)

  • 1. Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Lindskrog SV; Birkenkamp-Demtröder K; Nordentoft I; Laliotis G; Lamy P; Christensen E; Renner D; Andreasen TG; Lange N; Sharma S; ElNaggar AC; Liu MC; Sethi H; Aleshin A; Agerbæk M; Jensen JB; Dyrskjøt L
    Clin Cancer Res; 2023 Dec; 29(23):4797-4807. PubMed ID: 37782315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy.
    Ben-David R; Tillu N; Cumarasamy S; Alerasool P; Rich JM; Kaufmann B; Elkun Y; Attalla K; Mehrazin R; Wiklund P; Sfakianos JP
    Eur Urol Oncol; 2024 Oct; 7(5):1105-1112. PubMed ID: 38521660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
    Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
    Christensen E; Birkenkamp-Demtröder K; Sethi H; Shchegrova S; Salari R; Nordentoft I; Wu HT; Knudsen M; Lamy P; Lindskrog SV; Taber A; Balcioglu M; Vang S; Assaf Z; Sharma S; Tin AS; Srinivasan R; Hafez D; Reinert T; Navarro S; Olson A; Ram R; Dashner S; Rabinowitz M; Billings P; Sigurjonsson S; Andersen CL; Swenerton R; Aleshin A; Zimmermann B; Agerbæk M; Lin CJ; Jensen JB; Dyrskjøt L
    J Clin Oncol; 2019 Jun; 37(18):1547-1557. PubMed ID: 31059311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
    Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
    Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
    JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer.
    Christensen E; Nordentoft I; Birkenkamp-Demtröder K; Elbæk SK; Lindskrog SV; Taber A; Andreasen TG; Strandgaard T; Knudsen M; Lamy P; Agerbæk M; Jensen JB; Dyrskjøt L
    Clin Cancer Res; 2023 Apr; 29(8):1582-1591. PubMed ID: 36780195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.
    Butler TM; Boniface CT; Johnson-Camacho K; Tabatabaei S; Melendez D; Kelley T; Gray J; Corless CL; Spellman PT
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer.
    Bazargani ST; Clifford TG; Djaladat H; Schuckman AK; Wayne K; Miranda G; Cai J; Sadeghi S; Dorff T; Quinn DI; Daneshmand S
    Urol Oncol; 2019 Jan; 37(1):1-11. PubMed ID: 30470611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
    Teo MY; Guercio BJ; Arora A; Hao X; Regazzi AM; Donahue T; Herr HW; Goh AC; Cha EK; Pietzak E; Donat SM; Dalbagni G; Bochner BH; Olgac S; Sarungbam J; Sirintrapun SJ; Chen YB; Gopalan A; Fine SW; Tickoo SK; Reuter VE; Weigelt B; Schultheis AM; Funt SA; Bajorin DF; Solit DB; Iyer G; Ostrovnaya I; Rosenberg JE; Al-Ahmadie H
    Clin Genitourin Cancer; 2022 Oct; 20(5):431-441. PubMed ID: 35676169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
    Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
    Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
    Powles T; Assaf ZJ; Davarpanah N; Banchereau R; Szabados BE; Yuen KC; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Zimmermann BG; Sethi H; Aleshin A; Perdicchio M; Zhang J; Shames DS; Degaonkar V; Shen X; Carter C; Bais C; Bellmunt J; Mariathasan S
    Nature; 2021 Jul; 595(7867):432-437. PubMed ID: 34135506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.